Loading…
Loading…
On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 20,700 shares of the biotechnology company's stock, valued at approximately $1,216,000. Several other hedge funds and
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,948 shares of the biotechnology company's stock, valued at approximately $1,583,000. Other hedge funds and other institutional investors have also recently
Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 650,686 shares of the biotechnology company's stock, valued at approximately $38,215,000. Bamco Inc. NY owned approximately 0.81% of Veracyte at the
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Veracyte's 25.3% sell-off improves the entry price as strong core test demand and earnings growth face valuation, reimbursement and launch risks.